About Anavasi Diagnostics
Anavasi Diagnostics is a company based in Seattle (United States) founded in 2020 by Minh Duong, Robert Atkinson, and Barry Lutz. Anavasi Diagnostics has raised $6 million across 2 funding rounds from investors including NIH. Anavasi Diagnostics offers products and services including AscencioDx Molecular Detector and AscencioDx Covid-19 Test. Anavasi Diagnostics operates in a competitive market with competitors including Alveo Technologies, Luas Diagnostics, VIRIS Detection Systems, BioHermes and DxLab, among others.
- Headquarter Seattle, United States
- Founders Minh Duong, Robert Atkinson, Barry Lutz
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$6 M (USD)
in 2 rounds
-
Latest Funding Round
$14.9 M (USD), Grant
Nov 10, 2021
- Investors
-
Employee Count
Employee Count
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Anavasi Diagnostics
Anavasi Diagnostics offers a comprehensive portfolio of products and services, including AscencioDx Molecular Detector and AscencioDx Covid-19 Test.
Rapid portable tool for detecting SARS-CoV-2 in point-of-care settings.
Nucleic acid detection kit for SARS-CoV-2 variants in medical environments.
People of Anavasi Diagnostics
Unlock access to complete
Funding Insights of Anavasi Diagnostics
Anavasi Diagnostics has successfully raised a total of $6M across 2 strategic funding rounds. The most recent funding activity was a Grant round of $14.9 million completed in November 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 2
- Last Round Grant — $14.9M
-
First Round
First Round
(10 Nov 2021)
- Investors Count 1
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2021 | Amount | Grant - Anavasi Diagnostics | Valuation |
investors |
|
| Nov, 2021 | Amount | Angel Round - Anavasi Diagnostics | Valuation |
investors |
|
Investors in Anavasi Diagnostics
Anavasi Diagnostics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include NIH.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Drug discovery services are provided to the biopharma sector.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Anavasi Diagnostics
Financial Statements - Anavasi Diagnostics
Anavasi Diagnostics Comparisons
Competitors of Anavasi Diagnostics
Anavasi Diagnostics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Alveo Technologies, Luas Diagnostics, VIRIS Detection Systems, BioHermes and DxLab, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Cloud-powered POC MDx device
|
|
| domain | founded_year | HQ Location |
Sensors and connected app are developed for diabetes management.
|
|
| domain | founded_year | HQ Location |
CRISPR-based RNA-guided diagnostics for SARS-CoV-2 detection are developed.
|
|
| domain | founded_year | HQ Location |
Provider of POC diagnostic devices and kits
|
|
| domain | founded_year | HQ Location |
Point-of-care devices for infectious disease detection are developed.
|
Frequently Asked Questions about Anavasi Diagnostics
Anavasi Diagnostics was founded in 2020 and raised its 1st funding round 1 year after it was founded.
Anavasi Diagnostics is headquartered in Seattle, United States. It is registered at Seattle, Washington, United States.
Anavasi Diagnostics is a funded company, having raised a total of $6M across 2 funding rounds to date. The company's 1st funding round was a Grant of $14.9M, raised on Nov 10, 2021.
Anavasi Diagnostics was established in 2020 in Seattle, United States. Operations are centered in the diagnostics sector, with molecular detectors for COVID-19 produced as the primary focus. The company is led by co-founders Minh Duong, Robert Atkinson, and Barry Lutz, who also serves as chief scientific officer. Development and manufacturing of these diagnostic tools occur within the biotechnology field, targeting infectious disease testing needs in the region.
Anavasi Diagnostics's top competitors include Alveo Technologies, DxLab and BioHermes.
Anavasi Diagnostics offers AscencioDx Molecular Detector and AscencioDx Covid-19 Test.
Anavasi Diagnostics has 1 investor. Key investors include NIH.